Angiotensin-converting enzyme inhibitors in left ventricular dysfunction

Pharmacotherapy

Volumn 16, Issue 2 II, 1996, Pages

  Linn, William D ^a  

^a SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN; BRADYKININ; CAPTOPRIL; CILAZAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL MALEATE; FOSINOPRIL; LISINOPRIL; PERINDOPRIL; QUINAPRIL; RAMIPRIL; ZOFENOPRIL;

ACUTE HEART INFARCTION; CONGESTIVE HEART FAILURE; COUGHING; DRUG EFFICACY; DRUG MECHANISM; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE REMODELING; HOSPITAL ADMISSION; HUMAN; HYPERKALEMIA; HYPOTENSION; KIDNEY DISEASE; MORTALITY; PRIMARY MEDICAL CARE; QUALITY OF LIFE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SURVIVAL TIME;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; HUMANS; RANDOMIZED CONTROLLED TRIALS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0029921410     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Konstam MA, Dracup K, Baker DW, et al. Heart failure: evaluation and care of patients with left ventricular systolic dysfunction Clinical practice guideline no. 11. Rockville, MD: Agency for Health Care Policy and Research, Public Health Service, U.S. Department of Health and Human Services, 1994
2. Williams JF, Bristow MR, Fowler MB, et al. Guidelines for the evaluation and management of heart failure; report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on Evaluation and Management of Heart Failure). J Am Coll Cardiol 1995,26:1376-98.
3. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327 685-91
4. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure K Engl J Med 1991;325:293-302.
5. 1SIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. A randomized factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulfate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995;345:669-85.
6. Pfeffer MA, Braunwald E. Moyé LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial N Engl J Med 1992,327:669-77
7. Linn WD, Mulrow CD, Vanderwoud KJ. Impact of ACE inhibitors after acute myocardial infarction New York: Bristol-Myers Squibb, 1995
8. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 1987;316 1429-35
9. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991,325:303-10.
10. Kleber FX, Niemoller L, Doering W. Impact of converting enzyme inhibition on progression of chronic heart failure: results of the Munich mild heart failure trial. Br Heart J 1992,67-289-96
11. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure JAMA 1995,273.1450-6.
12. Colfer HT, Ribner HS, Gradman A, et al, for the Benazepril Heart Failure Study Group. Effects of once-daily benazepril therapy on exercise tolerance and manifestations of chronic congestive heart failure. AmJ Cardiol 1992;70:354-8.
13. McGarry R. Randomized, double blind, multicenter study comparing benazepril to digoxin and to placebo as add on therapy to diuretics in patients with CHF, NYHA Class II-III during a 12-week treatment period, GHBA-194. Summit, NJ: Ciba-Geigy Pharmaceuticals; September 1991. Unpublished report.
14. Magnani B, Magelli C, for the Multicenter Research Groups on Mild Heart Failure. Captopril in mild heart failure: preliminary observations of a long-term double-blind, placebocontrolled multicenter trial. Postgrad Med J 1986;62(suppl I): 153-8.
15. Bussmann WD, Storger H, Hadler D, et al. Long-term treatment of severe chronic heart failure with captopril: a double-blind randomized, placebo-controlled long-term study. J Cardiovasc Pharmacol 1987;9(suppl 2):S50-60.
16. Captopnl-Digoxin Multicenter Research Group. Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. JAMA 1988;259:539-44.
17. Newman TJ, Maskin CS, Dennick LG, et al. Effects of captopril on survival in patients with heart failure. Am J Med 1988;84(suppl 3A):140-4.
18. Barabino A, Galbariggi G, Pizzorni C, et al. Comparative effects of long-term therapy with captopril and ibopamine in chronic congestive heart failure in old patients. Cardiology 1991;78:289-96.
19. Kleber FX, Niemoller L, Doering W. Impact of converting enzyme inhibition on progression of chronic heart failure: results of the Munich mild heart failure trial Br Heart J 1992;67:289-96.
20. Drexler H, Banhardt BS, Meinertz T, et al. Contrasting peripheral short-term and long-term effects of converting enzyme inhibition in patients with congestive heart failure a double blind, placebo controlled trial. Circulation 1989;79:491-502.
21. Cleland JGF, Dargie HJ, Ball SG, et al. Effects of enalapril in heart failure: a double blind study of effects on exercise performance, renal function, hormones, and metabolic state. Br Heart J 1985;54:305-11.
22. Rucinska FJ. A double blind placebo controlled study to evaluate the effects of enalapril in patients with chronic heart failure. West Point. PA: Merck Sharpe & Dohme Research Laboratones, September 1991. Unpublished report.
23. Enalapril CHF Investigators. Long-term effects of enalapril in patients with congestive heart failure: a multicenter. placebocontrolled trial. Heart Failure 1987;3:102-7.
24. Dickstein K, Barvik S, Aarsland T. Effect of long-term enalapril therapy on cardiopulmonary exercise performance in men with mild heart failure and previous myocardial infarction. J Am Coll Cardiol 1991;18:596-602
25. Rucinska EJ. Enalapril vs placebo in previously untreated patients with CHF. West Point, PA: Merck Sharpe & Dohme Research Laboratories: September 1991. Unpublished report.
26. Zwehl W, Rucinska E, for the Lisinopril Chronic Heart Failure Investigators. Long-term effects of lisinopril in patients with chronic heart failure; a multicenter, placebo-controlled trial In: Nicholls MG, ed A focus on the clinical effects of a long acting ACE-inhibitors/heart failure New York, NY: Raven Press; 1990:31-40.
27. Giles TD, for the Lisinopril Chronic Heart Failure Group. Lisinopril treatment of congestive heart failure-results of a placebo controlled trial [abstr] Circulation 1990:82(suppl 4).III-323.
28. Rucinska EJ. Lisinopril first-line therapy in CHF. West Point, PA. Merck Sharpe & Dohme Research Laboratories; September 1991. Unpublished report.
29. Gilbert EM, Sandoval A, Larabee P, Renlund D, O'Connell JB, Bristow MR. Lisinopril lowers cardiac adrenergic drive and increases β-receptor density in the failing human heart. Circulation 1993;88.472-80.
30. Lechat P, Gamham J, Desche P, Bounhoure JP. Efficacy and acceptability of perindopril in mild to moderate chronic congestive heart failure. Am Heart J 1993;126:798-826.
31. Riegger GAJ The effects of ACE inhibitors on exercise capacity in the treatment of congestive heart failure. J Cardiovasc Pharmacol 1990;15(suppl 2):41-6.
32. Northridge DB, Rose E, Elder A, et al. A multicenter, double-blind, placebo-controlled trial of quinapril in mild chronic heart failure [abstr]. Eur Heart J 1991;12(suppl):184.
33. Uprichard A. A 16-week double blind, placebo-randomized placebo-controlled multicenter trial to evaluate the effects of withdrawal of quinapril hydrochloride on exercise tolerance in patients with mild to moderate congestive heart failure (906-276). Ann Arbor, MI: Parke-Davis Pharmaceutical Research; April 1994. Unpublished report.
34. Uprichard A. An 18-week double blind, operational titration, multicenter study to compare the efficacy and safety of orally administered quinapril hydrochloride with captopril and placebo in patients with congestive heart failure (906-226). Ann Arbor, MI. Parke-Davis Pharmaceutical Research, April 1994. Unpublished report.
35. Uprichard A. A 12-week double blind, placebo controlled study to determine the efficacy and safety of orally administered quinapril hydrochloride in patients with congestive heart failure (906-63) Ann Arbor, Mich: Parke-Davis Pharmaceutical Research; April 1994. Unpublished report.
36. Swedberg K, Amtorp O, Gundersen T, Remes J, Nilsson B. Is maximal exercise testing a useful method to evaluate treatment of moderate heart failure? [abstr] Circulation 1991,57.226.
37. Maass L. Double-blind comparative trail with ramipril and placebo in patients with heart failure (NYHA Class III-IV) stabilized on digitalis and furosemides. Frankfurt, Germany: Hoechst Aktiengesellschaft; October 1991 Unpublished report
38. Gordon M. Evaluating of the efficacy and safety of ramipril (HOE 498) in patients with congestive heart failure in a placebo-controlled trail Somerville, NJ: Hoechst-Roussel Pharmaceuticals; October 1991 Unpublished report
39. Maass L. Efficacy and safety of ramipril (HOE 498) in patients with congestive heart failure in a double blind placebo controlled trial. Frankfurt, Germany: Hoechst Aktiengesellschaft; October 1991. Unpublished report
40. Maass L. Evaluating of the effect of ramipril (HOE 498) on exercise duration, invasive cardiac hemodynamics profiles, and safety in patients with congestive heart failure. Frankfurt, Germany Hoechst Aktiengesellschaft, October 1991. Unpublished report.
41. Lemarie JC. Multicenter double-blind placebo controlled study of the efficacy and safety of ramipril administered orally for 24 weeks in the treatment of stable chronic congestive cardiac failure. Paris, France. Laboratories Hoechst; December 1992. Unpublished report
42. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821-8
43. Swedberg K, Held P, Kjekshus J, et al. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction Results of the cooperative new Scandinavian enalapril survival study II (CONSENSUS II). N EnglJ Med 1992,327.678-84.
44. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. G1SSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994;343.1115-22.
45. Chinese Cardiac Study Collaborative Group. Oral captopril versus placebo among 13,634 patients with suspected acute myocardial infarction: interim report from the Chinese cardiac study (CCS-1). Lancet 1995;345:686-7
46. Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. The effect of the angiotensin converting enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med 1995;332:80-5.
47. Pfeffer MA, Hennekens CH for the HEART Study Executive Committee. When a question has an answer: rationale for our early termination of the HEART trial. Am J Cardiol 1995;75:1173-5.
48. Pitt B. Use of converting enzyme inhibitors in patients with asymptomatic left ventricular dysfunction. J Am Coll Cardiol 1993;22(suppl A):158A-61.